Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant 9-valent HPV vaccine in healthy Chinese women aged 20-45 years
CTR20201791Phase 3Active
- Sponsor
- Beijing Health Guard
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus nonavalent vaccine in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), anal intraepithelial neoplasia (AIN), sponsored by Beijing Health Guard. Started Dec 2020; status: active.
02
Drugs
recombinant human papillomavirus nonavalent vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on CTR20201791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201791.